Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15810885 | 0.71 | CHRM2 (0.50) | CHRM2CHRM1CHRM3 | |
| SCHEMBL18403418 | 0.71 | CHRM2 (0.50) | CHRM2CHRM1CHRM3 | |
| SCHEMBL17572806 | 0.67 | CHRM2 (0.31) | CHRM2CHRM1CHRM3 | |
| SCHEMBL22606272 | 0.66 | — | — | |
| SCHEMBL20074563 | 0.64 | — | — | |
| SCHEMBL18653073 | 0.64 | — | — | |
| SCHEMBL22555094 | 0.62 | PREP (0.39) | PREPCHRM2CHRM1CHRM3 | |
| SCHEMBL22926902 | 0.62 | LMNA (0.41) | PREPCHRM2CHRM1CHRM3 | |
| SCHEMBL993595 | 0.62 | PREP (0.39) | PREPCHRM2CHRM1CHRM3 | |
| SCHEMBL4040776 | 0.62 | PREP (0.39) | PREPCHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020219808-A1 | DICARBAMATE INHIBITORS OF NS5A FOR TREATMENT OF HEPATITIS C VIRUS INFECTIONS AND RELATED DISEASES | BETA PHARMA, INC. (US) | 2020-10-29 | — | — | WO | disclosed |
| US-10787480-B2 | Cytotoxic peptides and conjugates thereof | NOVARTIS AG (CH) | 2020-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10787480-B2 | Cytotoxic peptides and conjugates thereof | CD47, NGLY1, VIP | PREP 184/4885CHRM2 4872/4885CHRM1 4832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.